INTRODUCTION
The exuberant public demand for stem cells has led to a rise in unregulated 'regenerative clinics' around the world offering unproven stem cell therapy of unknown quality and source for hundreds of diseases and conditions. 1 However, as illustrated by the recent approval in Europe of Alofisel (Takeda), 2 we are beginning to see emergence of pharmaceutical grade stem cell therapies. Properly controlled studies are ongoing to determine if stem cell therapy is a viable treatment option for many diseases and injury states. This review is focused on the status of preclinical rodent studies and clinical trials of mesenchymal stem/stromal cell (MSC) therapy for hemorrhagic stroke.
Hemorrhagic strokes account for 15% of all strokes, but are responsible for a disproportionate 40% of stroke-related deaths. 3, 4 Moreover, up to 50% of stroke patients are still dependent on care 1 year after initial ictus and report impairments in memory, speech, and daily activities. 5 Hemorrhagic stroke is caused by blood vessel rupture and subsequent extravasation of blood into the cranium, and can be further divided into subtypes based on the location of the bleed, including subarachnoid hemorrhage (SAH), 6 intracerebral hemorrhage (ICH), and intraventricular hemorrhage (IVH). Bleeding into the brain results in oxygen and glucose deprivation to perilesional tissue and initiates a secondary inflammatory response that contributes to lesion expansion, is detrimental to patient outcomes, and for which there is a dearth of therapeutics. 7, 8 Surgical therapies focused on acute hematoma evacuation continue to evolve, but their indication remains exceptional, 9, 10 whereas therapies targeted at inhibiting the secondary inflammatory cascade represent an important opportunity to improve patient survival, reduce functional disability, and offer hope to millions of patients worldwide.
MSCs have been extensively investigated as a treatment for ischemic stroke; however they have been less well studied for hemorrhagic stroke. [11] [12] [13] Nonetheless, more than 10 years of preclinical research investigating MSC therapy for hemorrhagic stroke exist and demonstrate functional improvements in a range of animal models of the disease. Therapeutic use of MSCs may repair or regenerate damaged neuronal cells and may reduce secondary neuroinflammatory cascades, which could improve patient outcomes. The first step towards translation from preclinical data to human trials is to build consensus around the safety and tolerability of MSCs to guide future research protocols and coordinate appropriate trial conditions. We may be at the cusp of overcoming these hurdles for hemorrhagic stroke, exemplified by several publications investigating MSCs therapy for hemorrhagic stroke in humans, and the listing of the first Phase I clinical trial for MSC therapy in hemorrhagic stroke in the United States. This review will focus on preclinical and clinical studies that have investigated MSCs for treatment of hemorrhagic stroke.
MSCs are multipotent stromal progenitor cells and the common precursors of bone, adipose, and cartilage tissue. They retain the ability to differentiate into these tissues, and possibly transdifferentiate into cells of other lineages such as neurons and glia. 14, 15 They are derived from easily accessible sources such as bone marrow, adipose tissue, umbilical cord tissue and the placenta, which make them appealing for therapeutics; 16 however, despite sharing a common name, MSC properties and functions can vary depending on their source of origin. For example, human placenta-derived MSCs have been reported to have a higher expansion and engraftment capacity than bone marrow-derived MSCs (BM-MSCs). 17, 18 Similarly, umbilical cord-derived (UC)-MSCs and adipose tissue-derived MSCs (AT-MSCs) have a higher proliferative capacity than BM-MSCs in vitro. 19, 20 Differences in epigenetics, 21 transcript expression, 22 in vivo engraftment, 21 cell surface expression, 23 and cytokine secretion 20 have also been reported among MSCs of different origins. In addition, significant donor-to-donor variability has been reported. 20 Unlike traditional drug therapies, MSC pharmacology once delivered into the body cannot be measured through customary pharmacokinetic/pharmacodynamic studies, thus elucidation of cell fate after MSC therapy is essential. Studies have demonstrated that within seconds the majority of intravenous administered MSCs are trapped within the lungs of rodent models, 24, 25 however, MSCs also have the ability to 'home in' on the site of injury. 26, 27 The exact mechanisms of this trafficking are still unknown, however expression of receptors and adhesion molecules such as chemokines and matrix metalloproteinases are likely involved in this cell migration. 28 Our understanding of these mechanisms is further complicated by variability in sourcing, culturing, and delivering MSCs. 29 Nonetheless, it is postulated that MSCs can mediate multiple mechanisms of action, which could make them ideal for the treatment of a wide range of degenerative and inflammatory diseases.
Preclinical research Investigation into MSC therapy for animal models of hemorrhagic stroke (Table 1 ; Fig. 1 ) has been performed for over ten years. Just over half of these studies used MSCs of human origin to treat intracranial hemorrhage, and the rest were sourced from rats. Around 60% of MSCs were sourced from bone marrow (BM-MSCs), as this is a viable source from both humans and rats, whereas umbilical/placental/amniotic-derived cells were used in about one quarter of the studies, and the rest derived from adipose tissue (AT-MSCs). The latter sources were all derived from human tissue. MSCs were generally characterized by expression of cell surface markers assessed through flow cytometry or immunohistochemical methods. MSCs were positive for CD29, CD44, CD73, CD90, and CD105 among others, and negative for the hematopoietic lineage markers, CD14, CD34, and CD45, the stem cell marker CD133, and the marker for endothelial cells, CD144, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] which is consistent with guidelines. 42 The delivery method for MSCs also varied, with under half of studies using stereotactically guided intracerebral injection, followed closely by intravenous administration, then intra-arterial and intranasal administration. Although the number of MSCs per dose ranged widely from 1 × 10 5 to 8 × 10 6 cells, they tended to split into two groups depending on the delivery method. MSCs delivered via intracerebral injection were given at an average dose of 6.4 × 10 5 cells per rat (range, 1 × 10 5 to 5 × 10 6 cells), whereas MSCs administered intravenously were given at an average dose that was four-fold higher at 2.6 × 10 6 cells per rat (range, 1 × 10 6 to 8 × 10 6 cells). Most studies administered MSCs within one day of injury, followed by between one day and one week after injury. Only one study assessed the efficacy of MSCs for the treatment of chronic stroke and administered MSCs two months after lesion to positive results. 38 Once administered, the engraftment and differentiation of MSCs into other cell types was assessed. BM-MSCs 30 and fetal/ neonatal tissue derived-MSCs 39, 43, 44 were found in the ipsilateral cortex and around the lesion area after intracerebral injection, suggesting that transplanted MSCs are capable of surviving in the perilesional space. Moreover, migration of BM-MSCs to perihematomal sites was observed following intranasal delivery after ICH. 45 Although there is consensus that migration and survival of MSCs is possible after intracerebral injection of MSCs, there is continued debate on whether MSC migration into the brain is observed with intravenously administrated MSCs. 31, 46 Similarly, groups reported that BM-MSCs, 30, 37, 38, 47, 48 AT-MSCs, 36 Wharton's jelly-derived MSCs, 43 and UC-MSCs 44, 46 were able to differentiate into neurons, astrocytes, and oligodendrocytes in the brain and incorporate into the cerebral vasculature, while others report that only a very small percentage of UC-MSCs differentiate into neurons and glia. 33 In contrast, Zhou and colleagues report that human amniotic MSCs do not co-localize with any neuronal or astrocyte markers one month after treatment, suggesting that MSCs do not differentiate at all. 39 Interestingly, AT-MSCs were easily detectable in the spleen up to 28 days after administration, 31 highlighting the role of the splenic response to stroke. 49 Most hemorrhagic stroke models used rats; two studies used C57BL/6J mice; 45, 50 and one used Macaca fascicularis monkeys (first in primate study). 51 Sprague-Dawley rats were the most commonly used, followed by Wistar rats, and two separate studies used the spontaneously hypertensive rat (SHR) model, which would seem well-suited for a cerebral hemorrhage model as hypertension is the primary risk factor of human intracerebral hemorrhage. 40, 52 All rat model-based papers investigated MSC treatment across groups of the same sex, with experiments heavily weighted towards male rats, thus it is not possible to reliably assess whether there are sex differences in response to MSC treatment based on animal model data alone. Studies in mouse and primate models were performed exclusively in male animals. 45, 50, 51 A number of well characterized experimental models are used to mimic hemorrhagic stroke in animals. 53 In the studies reviewed, two of the most common methods were employed: direct intracranial injection of whole blood or of bacterial collagenase. A single injection of blood into the intracranial space to mimic hemorrhage has been widely used for almost 40 years, 54, 55 and widely used in the current papers, with autologous blood sourced from the femoral vein or artery. 32, 51, 52, [56] [57] [58] One study also used fresh donor blood, such as maternal blood when 4 day old pups were used. 59 Injection of collagenase imitates hemorrhagic stroke by disrupting the extracellular matrix and opening the blood-brain barrier (BBB). 60 Collagenase injection was the most widely used method in the reviewed papers, and similarly to whole blood injection, was administered via direct intracranial stereotactic injection. Only one group perforated the Circle of Willis to induce bleeding, which is more appropriate as a model of human subarachnoid hemorrhage. 61 Though blood vs collagenase injection methods have been the subject of much debate, neither accurately reproduces all aspects of the human disease. However both protocols result in reproducible hematoma sizes and should continue to be used until better methods are developed. 53, 55, 62, 63 Changes in sensorimotor and mechanosensory function after MSC therapy were assessed by modified Neurologic Severity Scores (mNSS; a composite of motor, sensory, balance and reflex tests), limb motor function and modified-limb placing tests, corner turn tests, rotor rod performance, negative geotaxis tests (for newborn rats), modified Kito Score (neurological deficit score), adhesive removal test, Video-Tracking-Box test, and locomotor function evaluation. MSC therapy following stroke significantly attenuated impairment in these tests when compared to strokeonly control groups, 30, 31, [33] [34] [35] [36] [37] [38] [39] [40] [43] [44] [45] 48 ,51,52,56-59,61,64-66 except for Seyfried and colleagues who report no functional improvements in NSS and corner turn tests when rats were treated with 1 million BM-MSCs, 24 h post-ICH. 32 In contrast, the same group had previously reported significant improvements in NSS and corner turn tests in rats treated with 3, 5, and 8 million BM-MSCs. 58 Learning and memory were also tested in rodent models in the Morris water maze paradigm. Liao and colleagues 33 reported cognitive improvement after UC-MSC therapy with rats, demonstrating reduced latency to the platform compared to the strokeonly groups, which is in contrast to Cui et al., 56 who show no change in learning and memory between stroke-only and stroke with BM-MSC therapy groups.
Along with functional outcomes, gross measures of injury such as brain degeneration and lesion size were performed by histological inspection or magnetic resonance imaging (MRI) assessment. Treatment with BM-MSCs, 51, 58, 61 AT-MSCs, 64 UCMSCs, 34 and placenta-derived MSCs 41 after hemorrhagic stroke reduced gray and white matter loss 51, 61 -including reduced M.T. Turnbull et al. 64 and ipsilateral internal capsule loss 34 -as well as reduced perihematomal glial proliferation, 64 and decreased stroke-induced ventricular enlargement. 41 A conflicting report described no difference in striatal tissue volume between fibroblast-treated and BM-MSC-treated groups after stroke; however this was not compared to an ICH only group. 32 Hemorrhage volumes were also significantly reduced following BM-MSC, 35, 65 UC-MSC, 33, 66 and placenta-derived MSC 41 therapy compared to stroke only groups, and a comparison of administration methods within the same study found that both intracerebral and intraventricular routes of UC-MSC delivery significantly reduced hematoma volume when compared to stroke alone, but demonstrated no difference in hematoma volume when comparing the two methods of administration. 46 Only one study using AT-MSCs reported no change in lesion size as assessed by histology and MRI. 31 Brain edema after BM-MSC 37, 40, 56, 67 and placenta-derived MSC 41 treatment was significantly decreased by 1-10% following stroke injury compared to non-treated groups. Moreover, BM-MSC therapy prevented the development of post-hemorrhagic hydrocephalus (PHH) after severe IVH, and reduced compression of the periventricular corpus callosum induced by PHH. 59 Cerebral tissues, including cerebral arterial walls, were evaluated by electron microscopy, and BM-MSC therapy was found to improve the structural integrity of cerebral tissues, 68 and attenuate leakage of the BBB. 52 39 While the exact mechanisms by which MSCs exert their beneficial effects remain a matter of debate, there are data emerging that MSC-derived exosomes and other secreted factors have the same beneficial effects on hemorrhagic stroke as MSCs. 56, 69, 70 Therefore, it is likely that part of the therapeutic action of MSCs is mediated through paracrine secretion of cargobearing exosomes, and small molecules such as cytokines. This is exemplified in the current studies, which report that BM-MSC treatment decreased the levels of proinflammatory cytokines interleukin (IL)-1β, IL-2, IL-4, IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, 37, 40, 56, 67 and BM-MSCs 40 and UC-MSCs 59, 66 increased the levels of anti-inflammatory cytokines IL-10, transforming growth factor (TGF)-β1, IL-1α and IL-1β. These humoral factors can travel throughout the body and affect the biology of both proximal and distant responder cells. 71 BM-MSCs, 40, 61, 67 UCMSCs, 33, 59, 66 AT-MSCs, 64 and amniotic-derived MSCs, 39 were also shown to be immunomodulatory as exemplified by reduced astrogliosis, 59 ,61 downregulated density of Iba1, CD11b, ED1, CD68, and CD206 immunostained microglia and macrophages, 33, 39, 40, 61, 66, 67 and reduced myeloperoxidase (MPO) positive cells, which is representative of neutrophil activation. 33, 39, 64, 66, 67 Moreover, treatment with BM-MSCs, 40, 48 AT-MSCs, 64 UC-MSCs, 33, 59 and amniotic-derived MSCs 39 after experimental stroke significantly attenuated the increase in apoptotic and degenerating cells in the perihematomal area.
MSCs have also been shown to promote neurogenesis. This was investigated in a number of the reviewed studies through histochemical staining for markers of proliferating cells, immature neurons, and neuronal precursors. In the perihematomal regions, BM-MSC, 32, 47, 48, 58, 61 AT-MSC, 31 and amniotic-derived MSC 39 therapy increased the number of cells positive for these markers two fold, suggesting the presence of newly formed immature neurons. Growth factors also play a role in the therapeutic aspects of MSC function. Bone marrow- 45, 56, 57 and amniotic-derived MSC 39 transplantation rescued the levels of glial cell-derived neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF) that were downregulated as a result of experimental stroke, 39, 45 represented by increased phosphorylation of downstream signaling molecules. 56, 57 Moreover, blocking these signaling molecules with specific inhibitors blocked the therapeutic effects of MSCs. 57 Manipulation of BM-MSCs in vitro prior to use as therapy, such as with hypoxic preconditioning, rescued tissue loss after hemorrhagic stroke injury and reduced the subsequent enlargement of ventricle cavity size. 45 Similarly, priming of Wharton's jellyderived MSCs in vitro with a Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor increased the expression of GDNF and enhanced their therapeutic potential resulting in improved functional outcomes. 43 One study combined minimally invasive hematoma aspiration following ICH with UC-MSC treatment and demonstrated that the combination therapy is more effective than either therapy alone, 44 highlighting the potential of this application in human patients. These studies suggest that using combined approaches may be synergistic.
Clinical studies Clinical trials focused on MSC therapy for hemorrhagic stroke are currently limited. A search through clinicaltrials.gov comes back with only one result (currently recruiting); while conversely, MSC therapy for ischemic stroke presently lists 13 trials. Despite this underrepresentation in current clinical trials, six research articles have been published of completed trials and case series, ranging from 9 patients to 100, with a total patient count of 164 cases (39.6% female; 106 patients in treatment groups) reported in the literature (Table 2) . [72] [73] [74] [75] [76] [77] As with preclinical research, a range of sources was used to obtain MSCs. Bone marrow-derived MSCs, 73, 74, 77 and umbilical cord-derived MSCs 72, 74, 75 were the most often used in clinical trials. Bone marrow-derived mononuclear cells containing MSCs were also used, 76 and combination cell transplantation of olfactory ensheathing cells (OEC), neural progenitor cells (NPC), UC-MSCs, and Schwann cells (SCs) were tested. 75 The first publication for MSC therapy for hemorrhagic stroke was published in 2011 by Bhasin and colleagues. 73 They used autologous BM-derived MSCs administered intravenously at a dose of 50-60 million cells per patient, and followed up at 8 and 24 weeks. This study included a mix of hemorrhagic and ischemic lesions in the treatment group, and assessed functional recovery and imaging parameters in patients suffering from chronic stroke (3 months to 1 year post-lesion). Despite reporting improvements in functional testing from baseline to follow-up time points posttreatment, these improvements were observed in all groups and were not different between MSC-treated and control-treated patients.
Human studies included neurological impairment and functional assessment measures such as the National Institutes of Health Stroke Scale (NIHSS), the Glasgow Coma Scale (GCS), the Barthel Index (BI), modified Rankin scale (mRS), and the FuglMeyer assessment. In the five published cases of MSC treatment for hemorrhagic stroke that measured functional outcomes, four groups reported improvements in these measures relative to the control groups, which is in contrast to the original Bhasin 73 article, as well as improvements in other measures such as speech, breathing, and pain reporting. [74] [75] [76] [77] Moreover, computed tomography (CT) scans purportedly demonstrate accelerated hematoma reabsorption by 2 weeks after MSC transplantation in patients, however no statistical testing was performed to support this. 74 These functional effects were reported from 6 months to 5 years after MSC treatment, regardless of MSC source, dose, administration route or timing of treatment. Additionally, in contrast to preclinical rodent studies, human trials were not restricted to a treatment window within a day or week of stroke; instead these six studies were evenly distributed within a continuum of one week to greater than one year post-stroke. This is demonstrated by Tsang and colleagues 77 who treated patients with severe neurological disabilities one year after onset of ICH. They report improvements in modified BI and functional independence measures 16 weeks post-treatment and an improvement in extended GCS at 60 weeks post treatment when treated with autologous BM-MSCs. 77 Overall, almost all groups reported a lack of side effects. Patient follow ups for up to 5 years after treatment demonstrate that the therapy is well tolerated, and the trials report almost no adverse events, nor signs of de novo tumor development among patients. [72] [73] [74] [75] 77 The exception is Li et al., 76 who report that 5 patients (12.5% of their treatment group; compared to one patient (2.5%) in their control group) developed a low-grade fever (38.5°C), but this resolved within 3 days and without pharmaceutical intervention. This is consistent with a meta-analysis of MSCs in clinical trials which show a significant correlation between MSCs and transient fever, 78 and could support the idea that MSCs are immune-evasive and not immune-privileged. 79 Perhaps patientto-patient variability in immune system function underpins this finding. One patient was diagnosed with lung cancer four months after treatment; 76 however there is no direct evidence that cell therapy, or MSCs therapy specifically, leads to lung or other cancers. 78, 80 Despite this, treatment with MSCs still warrants further investigation into their long-term safety.
Biomarkers of injury and inflammation were investigated by one group in a Phase I clinical trial of MSC transplantation for severe intraventricular hemorrhage in premature infants. Ahn and colleagues 72 investigated the temporal profiles of inflammatory cytokines and growth factors in the CSF before and after intraventricular transplantation of umbilical cord blood-derived MSCs. They found reduced levels of the pro-inflammatory cytokine IL-6, but no changes in the levels of TGF-β1, TGF-β2, TNF-α, IL-β, VEGF, fibroblast growth factor (FGF) and BDNF; however this is reported in a premature immune system that might not be representative of an adult immune response. 81 This is also in contrast to biomarker profiles observed in rodent preclinical research, and highlights the need for further investigation in human patients, or better models for preclinical research.
CONCLUSION
Timing, dosage, and route of administration are all variables of an experimental intervention for hemorrhagic stroke that need to be properly considered, controlled for, and, ideally, tested. As stem cells are likely to act as a modulator of the inflammatory response and not as a reducer of ongoing bleeding, delivery is likely optimal beyond the first 24 h when the hematoma has effectively stopped expanding. Dose ranging studies specific to the intervention will need to be done to define ideal dose, which may not be the maximally tolerated dose, and routes of administration to be tested should be feasible in this patient population. As surgery is generally not recommended for hematomal decompression, indirect targeting of the hematomal lesion through intravenous infusion or other non-invasive route would have an appeal. Finally, as fevers are known to worsen neurological outcomes post-stroke, it would be important to closely monitor and, if necessary, mitigate the effects of fever in future trials.
Over 10 years of preclinical research has broadly demonstrated the effectiveness of MSC therapy in experimental hemorrhagic stroke. Moreover, small case studies and series in human hemorrhagic stroke patients have shown improvements in functional recovery with MSC therapy. Given the devastating effects of hemorrhagic stroke, and the millions of patients it affects, there is an understandable drive to develop this therapy for human use. Although a comprehensive understanding of the mechanisms of MSC therapy remains elusive, there is substantial evidence to the effectiveness of these cells as a therapy. A lack of mechanistic clarity has not always been a hurdle for drug development, 82 even in those as widely used as acetaminophen/paracetamol, 83 and penicillin. 84 Initial positive preclinical and clinical results strongly suggest that further investigation into MSC therapy for hemorrhagic stroke is warranted.
Reporting summary Further information on research design is available in the Nature Research Reporting Summary linked to this article.
